Lunai Bioworks heads into tomorrow's Q3 earnings print with a genuinely charged setup: short interest has more than doubled in a week, borrowing costs remain historically extreme, and the company itself has gone to war with the short sellers in court.
The most striking development this week is the naked short-selling lawsuit. Lunai filed a Delaware federal complaint naming "John Doe" defendants alleged to have traded roughly 554 million shares on a single day — March 17, 2026 — representing more than fifteen times the company's total shares outstanding. Law firms Dickinson Wright and Fox Rothschild are co-leading the suit. The filing added a combative dimension to a stock already generating significant short-side activity, and landed squarely in the same week that ORTEX flagged the borrow market as nearing a breaking point.
The short-side data tells a story of rapid escalation followed by a sudden partial unwind. Short interest as a share of free float climbed to nearly 19% earlier this week before pulling back to 12.9% on May 12. That's still a 44% jump from where it stood seven days prior. At the same time, cost to borrow peaked above 297% on May 11 — roughly double the April average — before easing to 169% by end of week. The pullback in both metrics on Tuesday is notable: it may reflect some shorts covering ahead of the earnings event or in response to the lawsuit headlines. Availability has loosened slightly in tandem, consistent with shorts returning borrowed shares rather than adding. The ORTEX short score of 77.7 places in an elevated tier of short pressure; it peaked above 80 intraday during the week.
The stock itself closed at $0.314 on May 12 — down 3% on the day and off 15% over the past month, with a YTD decline of 64%. Market cap is a micro-cap rounding to roughly $11 million. Against this backdrop the options market is showing a striking absence of defensive positioning. The put/call ratio runs at just 0.067, essentially at the low end of its 52-week range of 0.0 to 0.35, and right in line with its 20-day average. That reads as a near-total absence of downside hedging via options — unusual when short sellers have been this active. Ownership is highly concentrated: Rene Sindlev holds 9.8% of shares, with Laksya Ventures at 6.2% and Serhat Gümrükçü at 4.8%. No institutional manager of scale has a meaningful position.
The earnings history offers a sobering backdrop for tomorrow. The last two full earnings releases — February 2026 and November 2025 — produced next-day drops of 20% and 18% respectively, with five-day losses of 41% and 33%. The May 8 print showed a more contained 2.7% next-day decline, though that report coincided with the peak of the short-interest spike and a cost-to-borrow above 290%. Notably, the Q2 FY2026 results (December 2025 quarter) did show improvement: net loss narrowed to $1.8 million from $7.25 million a year earlier, and the company recently announced $20 million in new funding, suggesting some balance sheet runway heading into the report.
With Q3 earnings due May 14 and an approved reverse stock split (ratio of 1-for-3 to 1-for-30 authorised by shareholders) now sitting as a live option for management, the question for watchers is whether any short-squeeze dynamics materialise as borrowing costs remain elevated and shorts appear to have partially covered — or whether the earnings print reprices the equity lower and extinguishes that setup before it develops.
See the live data behind this article on ORTEX.
Open LNAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
